Search Results - "Vrdoljak, E"

Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma by Gore, M E, Szczylik, C, Porta, C, Bracarda, S, Bjarnason, G A, Oudard, S, Lee, S-H, Haanen, J, Castellano, D, Vrdoljak, E, Schöffski, P, Mainwaring, P, Hawkins, R E, Crinò, L, Kim, T M, Carteni, G, Eberhardt, W E E, Zhang, K, Fly, K, Matczak, E, Lechuga, M J, Hariharan, S, Bukowski, R

“…Background: We report final results with extended follow-up from a global, expanded-access trial that pre-regulatory approval provided sunitinib to metastatic…”
Get full text

Does metastatic colorectal cancer in elderly patients have specific features: the final results of a prospective phase II study of bevacizumab in combination with capecitabine as first-line treatment? by Omrcen, T., Katic, A., Tomic, S., Eterovic, D., Vrdoljak, E.

Get full text

Efficacy and safety of TC dose-dense chemotherapy as first-line treatment of epithelial ovarian cancer: a single-institution retrospective cohort study by Vrdoljak, J, Boban, T, Petrić Miše, B, Boraska Jelavić, T, Bajić, Ž, Tomić, S, Vrdoljak, E

“…The optimal first-line therapy of advanced ovarian cancer still remains questionable: standard paclitaxel-carboplatin (TC), dose-dense TC, intraperitoneal…”
Get full text

Final results of the TANIA randomised phase III trial of bevacizumab after progression on first-line bevacizumab therapy for HER2-negative locally recurrent/metastatic breast cancer by Vrdoljak, E., Marschner, N., Zielinski, C., Gligorov, J., Cortes, J., Puglisi, F., Aapro, M., Fallowfield, L., Fontana, A., Inbar, M., Kahan, Z., Welt, A., Lévy, C., Brain, E., Pivot, X., Putzu, C., González Martín, A., de Ducla, S., Easton, V., von Minckwitz, G.

“…The randomised phase III TANIA trial demonstrated that continuing bevacizumab with second-line chemotherapy for locally recurrent/metastatic breast cancer…”
Get full text

The European Code of Cancer Practice by Lawler, Mark, Oliver, Kathy, Gijssels, Stefan, Aapro, Matti, Abolina, Agnese, Albreht, Tit, Erdem, Sema, Geissler, Jan, Jassem, Jacek, Karjalainen, Sakari, La Vecchia, Carlo, Lievens, Yolande, Meunier, Françoise, Morrissey, Mike, Naredi, Peter, Oberst, Simon, Poortmans, Philip, Price, Richard, Sullivan, Richard, Velikova, Galina, Vrdoljak, Eduard, Wilking, Nils, Yared, Wendy, Selby, Peter

“…[Display omitted] •The Code is a citizen and patient-centred accessible statement of the core requirements for good clinical cancer practice.•The Code has 10…”
Get full text

A retrospective study of cancer testis antigens MAGE-A1 and MAGE-A4 expression in high grade endometrial cancer by Juretic, A, Srdelic Mihalj, S, Kuzmic-Prusac, I, Spagnoli, G, Vrdoljak, E, Petric-Mise, B, Capkun, V

Get full text

Pharmacoeconomic and clinical implications of sequential therapy for metastatic renal cell carcinoma patients in Central and Eastern Europe by Vrdoljak, E, Torday, L, Szczylik, C, Kharkevich, G, Bavbek, S, Sella, A

“…The incidence and mortality rates of kidney cancer in the Central and Eastern European (CEE) region are among the highest in the world. Access to second and…”
Get more information

Prognostic significance of MAPK, Topo IIα and E-cadherin immunoexpression in ovarian serous carcinomas by Sundov, D, Petric Mise, B, Mrklic, I, Bacic, B, Vrdoljak, E, Tomic, S

“…Ovarian cancer accounts for only 3% of all cancers in women but is the most lethal gynaecologic malignancy. Low-grade and high-grade ovarian serous carcinomas…”
Get more information

First-line treatment of advanced ovarian cancer with paclitaxel/carboplatin with or without epirubicin (TEC versus TC)—a gynecologic cancer intergroup study of the NSGO, EORTC GCG and NCIC CTG by Lindemann, K., Christensen, R.D., Vergote, I., Stuart, G., Izquierdo, M.A., Kærn, J., Havsteen, H., Eisenhauer, E., Ridderheim, M., Lopez, A.B., Hirte, H., Aavall-Lundquvist, E., Vrdoljak, E., Green, J., Kristensen, G.B.

“…The addition of anthracyclines to platinum-based chemotherapy may provide benefit in survival in ovarian cancer patients. We evaluated the effect on survival…”
Get full text

1952 Optimization of breast cancer patients' follow up - potential way to improve cancer care in transition countries by Vrdoljak, E, Soldic, Z, Gasparic, M, Boskovic, L, Belac Lovasic, I, Dabelic, N, Gugic, D, Ledina, D, Bozic Sakic, M, Raspovic, Z, Zorica, R, Trivanovic, D, Petkovic, M

Get full text

Microsatelite GT polymorphism in the toll-like receptor 2 is associated with colorectal cancer by Boraska Jelavić, T, Barišić, M, Drmic Hofman, I, Boraska, V, Vrdoljak, E, Peruzović, M, Hozo, I, Puljiz, Ž, Terzić, J

“…Factors underlying genetic predisposition for development of sporadic colorectal cancer are largely unknown. The fact that this cancer is more common in…”
Get full text

Retrospective analysis of efficacy of trastuzumab in adjuvant treatment of HER 2 positive early breast cancer - single institution experience by Ban, M, Viculin, J, Tomic, S, Capkun, V, Strikic, A, Mise, B Petric, Utrobicic, I, Vrdoljak, E

“…Addition of trastuzumab to chemotherapy is the cornerstone of adjuvant treatment of early HER2 positive breast cancer. Clinical trials and metaanalyses of…”
Get more information

Optimisation of breast cancer patients' follow‐up – potential way to improve cancer care in transitional countries by Bošković, L., Gašparić, M., Petrić Miše, B., Petković, M., Gugić, D., Ban, M., Jazvić, M., Dabelić, N., Belac Lovasić, I., Vrdoljak, E.

“…The aim of this analysis was to evaluate adherence of Croatian oncologists to follow‐up criteria as suggested by the current national and international…”
Get full text

Insights into cancer surveillance in Central and Eastern Europe, Israel and Turkey by Vrdoljak, E., Torday, L., Sella, A., Leyman, S., Bavbek, S., Kharkevich, G., Mardiak, J., Szczylik, C., Znaor, A., Wilking, N.

“…The current cancer landscape within transitional economies in central and Eastern Europe and the Mediterranean area is not particularly optimistic. Current…”
Get full text

PCN177 Assessment of Reimbursement Processes and Outcomes for Cancer Drugs in Croatia – Comparison to NICE and NCCN Guidelines by Vitezic, D, Vrdoljak, E, Bolanca, S

Get full text

Lapatinib in the treatment of HER-2 overexpressing breast cancer by Vrdoljak, E, Boban, M, Ban, M

“…Lapatinib is the only clinically available agent for the treatment of patients with human epidermal growth factor receptor-2 (HER-2) positive tumors that have…”
Get more information

Combination of capecitabine and mitomycin C as first-line treatment in patients with metastatic breast cancer by Vrdoljak, E, Boban, M, Omrcen, T, Hrepic, D, Fridl-Vidas, V, Boskovic, L

“…Optimal first-line chemotherapy for metastatic breast cancer (MBC) is challenging, particularly in patients previously treated with (neo) adjuvant…”
Get more information

Capecitabine and mitomycin-C in the therapy of pretreated patients with metastatic colorectal cancer: single center retrospective study with 36 patients by Vrdoljak, E, Omrcen, T, Boban, M, Hrepic, D

“…To evaluate the therapeutic effectiveness and safety of treatment with capecitabine and mitomycin-C (MMC) in patients with metastatic colorectal cancer…”
Get more information

Current state-of-the-art of concomitant chemoradiation in cervical carcinomas by Vrdoljak, E, Hamm, W

“…Despite screening programs, cervical carcinoma remains a major health problem throughout the world. Until recently pelvic radiation has been the standard…”
Get more information

Drug-induced hepatitis in a patient with malignant melanoma treated with interferon alfa 2b adjuvantly who had been administered gemfibrozil in therapy by Grubisić-Cabo, F, Vrdoljak, E

“…A well-known side effect of chemotherapy, covering a wide range of drugs, is drug-induced hepatitis. We are reporting on a 61-yr-old female patient whose…”
Get full text